



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1639  
EW


Applicant: Shohei Koide  
Title: ARTIFICIAL ANTIBODY POLYPEPTIDES  
Docket No.: 17027.003US1 Serial No.: 09/903,412  
Filed: July 11, 2001 Group Art Unit: 1639  
Examiner: Teresa D. Wessendorf

Commissioner for Patents  
P.O.Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the attached items (as indicated with an "X"):


- ☒ A return postcard.  
☒ A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copy of one reference.

VIKSNINS HARRIS & PADYS PLLP  
Customer Number 53137

By:   
Ann S. Viksnins  
Reg. No. 37,748

CERTIFICATE UNDER 37 CFR 1.8: The undersigned certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 26 day of September 2005.

  
Name

  
Signature



S/N 09/903,412

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Shohei Koide	Examiner:	Teresa D. Wessendorf
Serial No.:	09/903,412	Group Art Unit:	1639
Filed:	July 11, 2001	Docket No.:	17027.003US1
Title:	ARTIFICIAL ANTIBODY POLYPEPTIDES		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In accordance with the duty imposed by 37 C.F.R. § 1.156, and in accordance with 37 C.F.R. §§ 1.97 *et. Seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record. Pursuant to provisions of MPEP 609, Applicant requests that a copy of the Form PTO-Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. If necessary, please apply any charges or credits to Deposit Account No. 50-3503.

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 26 day of September 2005.

Lynda Mau  
Typed or Printed Name of Person Signing Certificate

Lynda Mau  
Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial Number: 09/903,412

Filing Date: July 11, 2001

Title: ARTIFICIAL ANTIBODY POLYPEPTIDES

---

Page 2

Dkt: 17027.003US1

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

SHOHEI KOIDE

By his Representatives,

VIKSNINS HARRIS & PADYS PLLP

P.O. Box 111098

St. Paul, MN 55111

(952) 876-4091

Date 26 September 2005

By 

Ann S. Viksnins

Reg. No. 37,748

Patent Office (37 C.F.R. § 1.98(b))	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17027.003US1	Application No. 09/903,412
	<b>Information Disclosure Statement          by Applicant</b> (Use several sheets if necessary)			Applicant Shohei Koide
				Group Art Unit 1639

U.S. Patent Documents[illegible]

### Foreign Patent Documents or Published Foreign Patent Applications

[illegible]

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
[T.W.]	AB	Dickinson et al., "Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor," J. Biol. Chem., 1997, 272:19875-19879

Examiner Signature	/Teresa Wessendorf/	Date Considered	5/15/08
--------------------	---------------------	-----------------	---------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.